{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:10:50Z","timestamp":1761109850640,"version":"build-2065373602"},"reference-count":88,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.ecl.2008.08.004","type":"journal-article","created":{"date-parts":[[2008,11,21]],"date-time":"2008-11-21T05:57:30Z","timestamp":1227247050000},"page":"923-942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Medications for Weight Reduction"],"prefix":"10.1016","volume":"37","author":[{"given":"George A.","family":"Bray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"1998","series-title":"Obesity: preventing and managing the global epidemic","author":"World Health Organization","key":"10.1016\/j.ecl.2008.08.004_bib1"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2008.08.004_bib2","first-page":"51S","volume":"6","year":"1998","journal-title":"Obes Res"},{"issue":"6","key":"10.1016\/j.ecl.2008.08.004_bib3","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1053\/j.gastro.2007.03.052","article-title":"The epidemiology of obesity","volume":"132","author":"Ogden","year":"2007","journal-title":"Gastroenterology"},{"year":"2007","series-title":"The metabolic syndrome and obesity","author":"Bray","key":"10.1016\/j.ecl.2008.08.004_bib4"},{"issue":"12","key":"10.1016\/j.ecl.2008.08.004_bib5","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/sj.ijo.0802475","article-title":"Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Padwal","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"12","key":"10.1016\/j.ecl.2008.08.004_bib6","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.289.12.1537","article-title":"Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis","volume":"289","author":"Shekelle","year":"2003","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ecl.2008.08.004_bib7","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","article-title":"Meta-analysis: pharmacologic treatment of obesity","volume":"142","author":"Li","year":"2005","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.ecl.2008.08.004_bib8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1124\/pr.59.2.2","article-title":"Pharmacological treatment of the overweight patient","volume":"59","author":"Bray","year":"2007","journal-title":"Pharmacol Rev"},{"issue":"6","key":"10.1016\/j.ecl.2008.08.004_bib9","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1210\/edrv.20.6.0383","article-title":"Current and potential drugs for treatment of obesity","volume":"20","author":"Bray","year":"1999","journal-title":"Endocr Rev"},{"issue":"6","key":"10.1016\/j.ecl.2008.08.004_bib10","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1053\/j.gastro.2007.03.053","article-title":"Drug treatment of the overweight patient","volume":"132","author":"Bray","year":"2007","journal-title":"Gastroenterology"},{"issue":"103","key":"10.1016\/j.ecl.2008.08.004_bib11","first-page":"1","article-title":"Pharmacological and surgical treatment of obesity","author":"Shekelle","year":"2004","journal-title":"Evid Rep Technol Assess (Summ)"},{"issue":"4","key":"10.1016\/j.ecl.2008.08.004_bib12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-277X.2004.00530.x","article-title":"What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions","volume":"7","author":"Avenell","year":"2004","journal-title":"J Hum Nutr Diet"},{"issue":"6","key":"10.1016\/j.ecl.2008.08.004_bib13","first-page":"505","article-title":"Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity","volume":"50","author":"Smith","year":"2001","journal-title":"J Fam Pract"},{"issue":"2","key":"10.1016\/j.ecl.2008.08.004_bib14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9343(98)00411-2","article-title":"Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine","volume":"106","author":"Apfelbaum","year":"1999","journal-title":"Am J Med"},{"issue":"9248","key":"10.1016\/j.ecl.2008.08.004_bib15","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group (Sibutramine Trial of Obesity Reduction and Maintenance)","volume":"356","author":"James","year":"2000","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ecl.2008.08.004_bib16","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jama.286.11.1331","article-title":"Long-term weight loss with sibutramine: a randomized controlled trial","volume":"286","author":"Wirth","year":"2001","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.ecl.2008.08.004_bib17","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/archinte.160.14.2185","article-title":"Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial","volume":"160","author":"McMahon","year":"2000","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.ecl.2008.08.004_bib18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1463-1326.2000.00081.x","article-title":"Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus","volume":"2","author":"Fujioka","year":"2000","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"10.1016\/j.ecl.2008.08.004_bib19","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1001\/jama.289.14.1805","article-title":"Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial","volume":"289","author":"Berkowitz","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ecl.2008.08.004_bib20","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1210\/jc.2004-0263","article-title":"Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study","volume":"90","author":"Godoy-Matos","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2008.08.004_bib21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-145-2-200607180-00005","article-title":"Effects of sibutramine treatment in obese adolescents: a randomized trial","volume":"145","author":"Berkowitz","year":"2006","journal-title":"Ann Intern Med"},{"issue":"15","key":"10.1016\/j.ecl.2008.08.004_bib22","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1161\/01.CIR.0000161369.71722.10","article-title":"Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment","volume":"111","author":"Daniels","year":"2005","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.ecl.2008.08.004_bib23","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa050156","article-title":"Randomized trial of lifestyle modification and pharmacotherapy for obesity","volume":"353","author":"Wadden","year":"2005","journal-title":"N Engl J Med"},{"issue":"9123","key":"10.1016\/j.ecl.2008.08.004_bib24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients: European Multicentre Orlistat Study Group","volume":"352","author":"Sjostrom","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ecl.2008.08.004_bib25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"issue":"23","key":"10.1016\/j.ecl.2008.08.004_bib26","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","article-title":"Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial","volume":"293","author":"Chanoine","year":"2005","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ecl.2008.08.004_bib27","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","article-title":"Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study","volume":"21","author":"Hollander","year":"1998","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ecl.2008.08.004_bib28","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/diacare.25.6.1033","article-title":"Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial","volume":"25","author":"Kelley","year":"2002","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ecl.2008.08.004_bib29","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","article-title":"Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin","volume":"25","author":"Miles","year":"2002","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ecl.2008.08.004_bib30","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/archinte.160.9.1321","article-title":"Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults","volume":"160","author":"Heymsfield","year":"2000","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.ecl.2008.08.004_bib31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/00912709922007543","article-title":"Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients","volume":"39","author":"Zhi","year":"1999","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ecl.2008.08.004_bib32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/oby.2000.53","article-title":"Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial","volume":"8","author":"Wadden","year":"2000","journal-title":"Obes Res"},{"issue":"4","key":"10.1016\/j.ecl.2008.08.004_bib33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/j.1550-8528.1995.tb00160.x","article-title":"Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects","volume":"3","author":"Lawton","year":"1995","journal-title":"Obes Res"},{"issue":"Suppl 3","key":"10.1016\/j.ecl.2008.08.004_bib34","first-page":"481S","article-title":"Efficacy and safety of long-term fluoxetine treatment of obesity: maximizing success","volume":"4","author":"Goldstein","year":"1995","journal-title":"Obes Res"},{"issue":"9","key":"10.1016\/j.ecl.2008.08.004_bib35","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/oby.2001.71","article-title":"Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women","volume":"9","author":"Gadde","year":"2001","journal-title":"Obes Res"},{"issue":"10","key":"10.1016\/j.ecl.2008.08.004_bib36","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/oby.2002.142","article-title":"Bupropion SR vs placebo for weight loss in obese patients with depressive symptoms","volume":"10","author":"Jain","year":"2002","journal-title":"Obes Res"},{"issue":"7","key":"10.1016\/j.ecl.2008.08.004_bib37","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/oby.2002.86","article-title":"Bupropion SR enhances weight loss:\u00a0a 48-week double-blind, placebo-controlled trial","volume":"10","author":"Anderson","year":"2002","journal-title":"Obes Res"},{"issue":"Suppl","key":"10.1016\/j.ecl.2008.08.004_bib38","first-page":"167S","article-title":"Topiramate: a new potential pharmacological treatment for obesity","volume":"12","author":"Astrup","year":"2004","journal-title":"Obes Res"},{"issue":"4","key":"10.1016\/j.ecl.2008.08.004_bib39","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/oby.2003.78","article-title":"Predictors of weight loss in adults with topiramate-treated epilepsy","volume":"11","author":"Ben-Menachem","year":"2003","journal-title":"Obes Res"},{"issue":"6","key":"10.1016\/j.ecl.2008.08.004_bib40","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/oby.2003.102","article-title":"A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity","volume":"11","author":"Bray","year":"2003","journal-title":"Obes Res"},{"issue":"11","key":"10.1016\/j.ecl.2008.08.004_bib41","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/sj.ijo.0802783","article-title":"A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects","volume":"28","author":"Wilding","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"10","key":"10.1016\/j.ecl.2008.08.004_bib42","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/oby.2004.206","article-title":"Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects","volume":"12","author":"Astrup","year":"2004","journal-title":"Obes Res"},{"issue":"14","key":"10.1016\/j.ecl.2008.08.004_bib43","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1001\/jama.289.14.1820","article-title":"Zonisamide for weight loss in obese adults: a randomized controlled trial","volume":"289","author":"Gadde","year":"2003","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ecl.2008.08.004_bib44","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/WNL.54.4.973","article-title":"Stable weight during lamotrigine therapy: a review of 32 studies","volume":"54","author":"Devinsky","year":"2000","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ecl.2008.08.004_bib45","doi-asserted-by":"crossref","first-page":"258","DOI":"10.4088\/JCP.v67n0212","article-title":"A single-center, double-blind, placebo-controlled evaluation of lamotrigine in the treatment of obesity in adults","volume":"67","author":"Merideth","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.ecl.2008.08.004_bib46","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/diacare.19.9.920","article-title":"The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution: BIGPRO study group","volume":"19","author":"Fontbonne","year":"1996","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ecl.2008.08.004_bib47","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ecl.2008.08.004_bib48","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1210\/jc.2004-1965","article-title":"Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome","volume":"90","author":"Ortega-Gonzalez","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2008.08.004_bib49","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2337\/diacare.29.02.06.dc05-1267","article-title":"Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1","volume":"29","author":"Riddle","year":"2006","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ecl.2008.08.004_bib50","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet Med"},{"issue":"12","key":"10.1016\/j.ecl.2008.08.004_bib51","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.metabol.2003.06.003","article-title":"Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis","volume":"52","author":"Maggs","year":"2003","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.ecl.2008.08.004_bib52","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1381\/0960892041590818","article-title":"The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery","volume":"14","author":"Patriti","year":"2004","journal-title":"Obes Surg"},{"issue":"5","key":"10.1016\/j.ecl.2008.08.004_bib53","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2174\/1568007043336950","article-title":"Gut hormones as peripheral anti-obesity targets","volume":"3","author":"Small","year":"2004","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"issue":"10","key":"10.1016\/j.ecl.2008.08.004_bib54","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1001\/archsurg.137.10.1109","article-title":"Effects of obesity surgery on non\u2013insulin-dependent diabetes mellitus","volume":"137","author":"Greenway","year":"2002","journal-title":"Arch Surg"},{"issue":"2","key":"10.1016\/j.ecl.2008.08.004_bib55","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/s-2004-814222","article-title":"Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion","volume":"36","author":"Lugari","year":"2004","journal-title":"Horm Metab Res"},{"issue":"6","key":"10.1016\/j.ecl.2008.08.004_bib56","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1210\/endo.141.6.7490","article-title":"Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats","volume":"141","author":"Szayna","year":"2000","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.ecl.2008.08.004_bib57","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1210\/en.2004-1349","article-title":"Exenatide (exendin-4) improves insulin sensitivity and beta-cell mass in insulin-resistant obese fa\/fa Zucker rats independent of glycemia and body weight","volume":"146","author":"Gedulin","year":"2005","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.ecl.2008.08.004_bib58","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1053\/meta.2000.6251","article-title":"Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats","volume":"49","author":"Rodriquez de Fonseca","year":"2000","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.ecl.2008.08.004_bib59","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","article-title":"Entry of exendin-4 into brain is rapid but may be limited at high doses","volume":"27","author":"Kastin","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"1","key":"10.1016\/j.ecl.2008.08.004_bib60","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1152\/ajpendo.2001.281.1.E155","article-title":"Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers","volume":"281","author":"Edwards","year":"2001","journal-title":"Am J\u00a0Physiol Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2008.08.004_bib61","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/dmrr.499","article-title":"Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes","volume":"20","author":"Fineman","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"10.1016\/j.ecl.2008.08.004_bib62","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ecl.2008.08.004_bib63","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ecl.2008.08.004_bib64","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.ecl.2008.08.004_bib65","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann Intern Med"},{"issue":"9468","key":"10.1016\/j.ecl.2008.08.004_bib66","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study","volume":"365","author":"Van Gaal","year":"2005","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ecl.2008.08.004_bib67","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia","volume":"353","author":"Despres","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ecl.2008.08.004_bib68","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial","volume":"295","author":"Pi-Sunyer","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2008.08.004_bib69","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","article-title":"RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study","volume":"368","author":"Scheen","year":"2006","journal-title":"Lancet"},{"issue":"2\u20133","key":"10.1016\/j.ecl.2008.08.004_bib70","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0014-2999(02)01427-9","article-title":"Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status","volume":"440","author":"Parker","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.ecl.2008.08.004_bib71","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cmet.2006.08.002","article-title":"Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults","volume":"4","author":"Erondu","year":"2006","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.ecl.2008.08.004_bib72","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/oby.2007.620","article-title":"Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss","volume":"15","author":"Erondu","year":"2007","journal-title":"Obesity (Silver Spring)"},{"issue":"6","key":"10.1016\/j.ecl.2008.08.004_bib73","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1139\/y04-025","article-title":"Mutational analysis of the serotonin receptor 5-HT2C in severe early-onset human obesity","volume":"82","author":"Gibson","year":"2004","journal-title":"Can J Physiol Pharmacol"},{"issue":"14","key":"10.1016\/j.ecl.2008.08.004_bib74","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1021\/jm058240i","article-title":"5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents","volume":"49","author":"Nilsson","year":"2006","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.ecl.2008.08.004_bib75","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/ajcn\/56.5.863","article-title":"Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan","volume":"56","author":"Cangiano","year":"1992","journal-title":"Am J Clin Nutr"},{"issue":"7","key":"10.1016\/j.ecl.2008.08.004_bib76","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/sj.ijo.0800642","article-title":"Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non\u2013insulin-dependent diabetic patients","volume":"22","author":"Cangiano","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"2","key":"10.1016\/j.ecl.2008.08.004_bib77","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00427624","article-title":"Effect of anorexic drugs on food intake and the micro-structure of eating in human subjects","volume":"66","author":"Rogers","year":"1979","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.ecl.2008.08.004_bib78","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0031-9384(95)02098-5","article-title":"Effect of fenfluramine on food intake, mood, and performance of humans living in a residential laboratory","volume":"59","author":"Foltin","year":"1996","journal-title":"Physiol Behav"},{"issue":"5","key":"10.1016\/j.ecl.2008.08.004_bib79","first-page":"299","article-title":"The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks","volume":"19","author":"Drent","year":"1995","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.ecl.2008.08.004_bib80","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/BF02244883","article-title":"m-Chlorophenylpiperazine decreases food intake in a test meal","volume":"116","author":"Walsh","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.ecl.2008.08.004_bib81","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s002130050178","article-title":"Sumatriptan decreases food intake and increases plasma growth hormone in healthy women","volume":"129","author":"Boeles","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2008.08.004_bib82","first-page":"A80","article-title":"APD356, an orally-active selective 5-HT2C agonist reduces body weight in obese men and women","volume":"55","author":"Smith","year":"2006","journal-title":"Diabetes Metab"},{"issue":"Suppl","key":"10.1016\/j.ecl.2008.08.004_bib83","first-page":"S135","article-title":"Increased fecal fat excretion in normal volunteers treated with lipase inhibitor ATL-962","volume":"26","author":"Dunk","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"3","key":"10.1016\/j.ecl.2008.08.004_bib84","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.ijo.0803446","article-title":"Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients","volume":"31","author":"Kopelman","year":"2007","journal-title":"Int J Obes (Lond)"},{"issue":"5","key":"10.1016\/j.ecl.2008.08.004_bib85","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/clpt.1992.68","article-title":"Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study","volume":"51","author":"Weintraub","year":"1992","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.ecl.2008.08.004_bib86","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/archinte.163.9.1046","article-title":"National trends in antiobesity medication use","volume":"163","author":"Stafford","year":"2003","journal-title":"Arch Intern Med"},{"issue":"9","key":"10.1016\/j.ecl.2008.08.004_bib87","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ecl.2008.08.004_bib88","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1210\/jc.2006-1740","article-title":"Lack of an effect of a novel beta-3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study","volume":"92","author":"Redman","year":"2007","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852908000571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852908000571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:32:39Z","timestamp":1760175159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852908000571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":88,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0889852908000571"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2008.08.004","relation":{},"ISSN":["0889-8529"],"issn-type":[{"type":"print","value":"0889-8529"}],"subject":[],"published":{"date-parts":[[2008,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medications for Weight Reduction","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2008.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}